TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate
Description: Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Needling and Lavage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Needling and Lavage
Study: NCT00480883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglumine antimoniate, allopurinol
Description: first drug in injectable, second is in tablet form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglumine antimoniate
Description: injectable 20 mg/kg/day/intramuscular for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meglumine antimoniate, allopurinol
Description: injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
Study: NCT01880281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat and vegetable diet
Description: After having a diet of 3 days and the investigational's day, the volunteers will have the other diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat and vegetable diet
Description: After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
Study: NCT03380715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal nebulisation into the right nostril
Description: 400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal nebulisation into the right nostril
Description: 400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray into the right nostril
Description: Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray into the right nostril
Description: Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
Study: NCT01744873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate Tablet 10 mg
Description: 10 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 10 mg tablet once a day
Study: NCT02234232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
Study: NCT03505554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: 100 mg QD
Study: NCT01330030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 6mg/24 hrs for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: placebo/24hrs for 8 weeks
Study: NCT02410551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 200 mg by mouth twice a day for 60 days.
Study: NCT03780790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: % 0,25
Study: NCT04304534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.
Study: NCT02410551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone calls made by study staff to participant on second and third week of each month.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
Study: NCT02104869

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (inactivated and fragmented).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (inactivated and fragmented).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (inactivated and fragmented).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (inactivated and fragmented).
Study: NCT04622124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasted vs. high-fat meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02663882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self control practice - smoking related task
Description: participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self control practice - non-smoking related task
Description: participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
Study: NCT00122447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325 mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: 600 mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 40 mg PO QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD
Study: NCT01279382

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypnotherapy (HYP)
Description: Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation training (RT)
Description: RT was given to a subgroup of patients as intervention in IBS treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual (CON)
Description: CON was given to a subgroup of patients as control intervention in IBS treatment
Study: NCT04360408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis
Description: The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
Study: NCT00361478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education
Description: Weekly exercise and education program for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Written educational material
Study: NCT02959008

Intervention type: DEVICE
Intervention: measure TOI and BP
Description: Both groups measure TOI and BP.

Intervention type: DEVICE
Intervention: measure TOI and BP
Description: Both groups measure TOI and BP.
Study: NCT03749954

Intervention type: DIAGNOSTIC_TEST
Intervention: Detachable string magnetically controlled capsule endoscopy
Description: Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
Study: NCT00117806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: SCI-VIP: Supported employment implemented for veterans with spinal cord injury.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Arm 2
Description: Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
Study: NCT04114942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Never Coach
Description: 20 weeks of didactic training and 10 weeks of internship, but no coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internship Only Coach
Description: 20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
Study: NCT01419626

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Interdental cleaning device with water
Description: Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental cleaning device with essential-oil mouthrinse
Description: Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
Study: NCT03123367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Nella VuSleeve
Description: Sleeve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Nella NuSpec
Description: Speculum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: NellaSpec
Description: Speculum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 4: Nella Insert
Description: Sleeve
Study: NCT04610385

Intervention type: PROCEDURE
Intervention: radical cystectomy with urinary diversion
Description: surgical removal of the urinary bladder and other organs and perform a urinary shunt

Intervention type: PROCEDURE
Intervention: radical cystectomy with urinary diversion
Description: surgical removal of the urinary bladder and other organs and perform a urinary shunt
Study: NCT04137627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 MG Oral Capsule
Description: The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The administration of placebo capsule in addition to neoadjuvant chemotherapy
Study: NCT02053870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy+conventional treatment
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
Study: NCT02609828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanezumab
Description: Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
Study: NCT00963222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 3 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap placebo/day for 3 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap placebo/day for 3 month
Study: NCT04553679

Intervention type: BEHAVIORAL
Intervention: Mindfulness online intervention
Description: A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.

Intervention type: BEHAVIORAL
Intervention: Mindfulness online intervention
Description: A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
Study: NCT00333840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesilate
Description: imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesilate
Description: imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha (INF-a)
Description: interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
Study: NCT00333840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha (INF-a)
Description: interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine (ARA-C)
Description: cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Study: NCT02754297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Octreotate
Description: * The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles.
Study: NCT00754572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25mg oral or parenteral weekly.
Study: NCT03544463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Description: The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
Study: NCT04406454

Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
Study: NCT00863304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 10 mg
Description: tanezumab 10 mg one dose at weeks 0 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 5 mg
Description: tanezumab 5 mg one dose at weeks 0 and 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 1000 mg daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match tanezumab and naproxen dosing
Study: NCT03405350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redon-sulfide baths
Description: Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Mud Baths
Description: duration: 20 minutes, temperature 40-42 degrees Celsius

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Terrain Therapy
Description: walking, outdoors physical activities,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Massage
Description: Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency Magnetic Field
Description: duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonotherapy
Description: treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Light Therapy
Description: blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
Study: NCT03007433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 400ml of Liquid Nutrient Drink
Description: 12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 400ml of Liquid Nutrient Drink
Description: 12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
Study: NCT02510586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed